Health
China Zhifei’s COVID vaccine largely works on delta variant: study – Nikkei Asia
Efficacy results from Phase 3 clinical trial yet to be published
BEIJING (Reuters) — A COVID-19 vaccine developed by a unit of China’s Chongqing Zhifei Biological Products largely retained its neutralising effect against the Delta variant but there was a slight reduction, Chinese researchers found in a laboratory study.
…
Continue Reading
-
Business19 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business18 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News15 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business15 hours ago1 ASX dividend stock down 43% I’d buy right now